The efficacy of glucocorticoids in treatment of HBV-associated acute-on-chronic liver failure in the early stage

Sen LUO,Zhong-ji MENG,Zuo-jiong GONG

DOI: https://doi.org/10.3969/j.issn.1005-0264.2018.02.004

2018-01-01

Abstract:Objective:To investigate the efficacy and safety of glucocorticoids in treatment of patients with HBV-associated acute-on-chronic liver failure (HBV-ACLF) in the early stage and in pre-ACLF.Methods:Sixty-five patients with HBV-ACLF in the early stage or preACLF admitted in the department of infectious diseases of Taihe Hospital,Hubei University of Medicine,from Dec 2014 to Aug 2017,were enrolled in this retrospective study.All the patients received standard medical treatment including energy supplements and antiviral therapy using Entecavir or Tenofovir disoproxil,in which 30 patients received glucocorticoids treatment were assigned to treatment group,and the rest 35 patients were set as control group.A 7-day glucocorticoids regimen were applied with Methylprednisolone Sodium Succinate intravenously at the dose of 40mg per day or with Dexamethasone Sodium Phosphate at the dose of 5mg per day via retention enema.All the data including the clinical symptoms,liver function biochemical indexes,4 weeks survival rates and complications were retrieved from the electronic medical record system of Taihe Hospital.Results:After 1 week treatment with glucocorticoids,the total bilirubin was decreased from 201.5 ± 87.3moL/L to 35.4 ±58.9mol/L and the prothrombin activity was raised from 42.8 ± 12.2％ to 64.0 ± 17.1％ in the treatment group.The improvement rates of clinical symptoms and biochemical indexes were significantly higher in patients in the treatment group than those in control group,and the incidences of infection and hepatic encephalopathy were reduced significantly in patients received glucocorticoids treatment.It is noteworthy that glucocorticoids treatment can not only significantly raise the survival rates of patients with HBV-ACLF (96.7％ vs 77.1％;P ＜ 0.05),but also protect most patients with pre-ACLF from acute deterioration,much less patients with pre-ACLF developed ACLF in treatment group (7.7％) than in control group (73.3％) (P ＜ 0.01).During the treatment,there were no remarkable glucocorticoid-associated adverse event or side effect.Conclusion:The glucocorticoids treatment is effective and safe for patients with HBV-ACLF in the early stage and pre-ACLF,protecting liver function from deterioration,reducing complications,and improving the outcomes.